Storm Therapeutics

📢 We’ve announced a $56 million Series C financing to support the advancement of STC‑15, our first‑in‑class, oral small‑molecule METTL3 inhibitor. The first patient has now been dosed in a Phase 2 monotherapy trial in selected sarcoma indications. bit.ly/3QeVxMH

Excited to team up with AlidaBio to explore how METTL3 inhibition affects RNA regulation in cancer patients. We're using AlidaBio's advanced sequencing platforms to analyze samples from our Phase 1/2 trials with STC-15, our first-in-class METTL3 inhibitor. bit.ly/49tpJd5

Meet STORM at @ELRIG_SCIENCE Drug Discovery 2025! Join us for our poster presentations to explore the critical role of RNA-binding proteins in cellular replication stress mechanisms. 📍 Poster #163 📅 21 & 22 Oct 🕐 13:00-13:45 BST 📌 Beside the Tech Theatre

📢 Discovery data to be unveiled at AACR-NCI-EORTC 2025 📢 STORM Therapeutics will present new data on #STM11315, its allosteric, potent & selective #DHX9 helicase inhibitor, on 24 October. 🗣️ Oral Presentation: 5:26–5:36 PM EDT 📌 Poster Presentation: 12:30–4:00 PM EDT

📣 Appointment news from STORM! We're excited to welcome veteran cancer drug developer Eric Martin as Chief Development Officer as we advance our METTL3 inhibitor STC-15 through Phase 1b/2 development.🔗 Learn more: bit.ly/44yokjU #oncology #biotech #drugdevelopment

Clinical milestone achieved & CMO appointed! The #firstpatient has been dosed in our collaboration with Coherus Biosciences, commencing a Phase 1b/2 study with STC-15 in combination with Coherus’s next generation PD-1 inhibitor, LOQTORZI® (toripalimab). bit.ly/3Z5nlVv

Look out for the #STORM team at London Life Sciences Week! Our CEO, Jerry McMahon, will attend the upcoming @Jefferies London Healthcare Conference from 19-21 November alongside our CBO, Marguerite Hutchinson.

Our Group Leader, Molecular Cell Biology, Alexandra Sapetschnig, is presenting at RNA Modifications and Epitranscriptomics on 15 November from 11:20-11:40 CET! Come along to hear about #STORM's first-in-class #METTL3 inhibitor #STC15 and new #clinical data presented at #SITC2024.

Check out the latest insights from our CEO, Jerry McMahon, featured in an article by International Clinical Trials discussing the current field of Alzheimer’s disease, drugs, biomarkers, and the future of treatment options for #neurogenerativediseases: bit.ly/3YJimc7

Read the press release here: bit.ly/3YYBaFy

#STORM presents new #clinical data at #SITC2024 from its Phase 1 study evaluating #STC15. Highlights include promising signs of clinical activity observed in multiple tumor types and gene expression data showed upregulation of innate immunity pathways. Read more in the comments👇

Visit our poster presentation at #SITC2024! 📝 Title: Phase 1 dose escalation and cohort expansion study evaluating safety, PK, PD and clinical activity of STC-15, a METTL3 inhibitor, in patients with advanced malignancies 📅 Date: Saturday 9 November 📌 Abstract number: 676

STORM is in Barcelona for the EORTC-NCI-AACR (#ENA) Symposium! Poster details below 👇 📢 Session Title: New therapies in immuno oncology 📅 Session Date and Time: 25 October, 09:00 - 15:00 CEST 🏢 Location: Exhibition Hall 📌 Catalog Number: 451 🗞️ Presentation Number: PB439

Thanks to @Cambridge_Uni for spotlighting us as one of '10 Cambridge spinouts changing the story of cancer'! Check out STORM in the article 👇 and discover how we are pioneering cellular reprogramming through RNA modifications to treat disease🧬#lifesciences #biotech #cancer

Read the press release here: bit.ly/481AC4x

#STORM is presenting a poster on its updated interim results from its ongoing Phase 1 trial with lead product, STC-15, at the ENA Symposium! STC-15 is a potent and selective oral small molecule that inhibits METTL3. 💡 Find out more in the press release linked in the comments.

Meet the #STORM team at @ELRIG_UK Drug Discovery 2024 on the 📅2-3 October at the 📍ExCel in London, where will be presenting the poster, 'Working towards pandemic preparedness: Inhibiting viral 5' RNA cap methylation with potent, selective, broad-spectrum small molecules'.

Our CEO, Jerry McMahon, provides insight into the potential of STORM's lead product STC-15 "across multiple therapeutic areas" in @DDWJournal's article which delves into the new mechanisms of action, receptors and modalities in cancer immunotherapy, here: bit.ly/3Zxmy0s

#STORM's Senior Vice President Therapeutics, Matthew Fyfe, is chairing a session at the International Symposium on Medicinal Chemistry! 📢 Title: Session 4 'Chemical Biology': Targeting RNA and RNA-Regulatory Proteins 🕐 Date & Time: 2nd September, 13:45 CEST 📍 Rome, Italy

Great to see STORM's CEO, Jerry McMahon, featured in @Citeline's discussion on advancements in #oncology and the use of technology in the evolving landscape of drug development. 💡 An insightful discussion amongst experts from #ASCO2024! Read here: bit.ly/3AE1x9S